Sofosbuvir-ribavirin combo shows promise for hepatitis C

04/24/2013 | HealthDay News

A study in the New England Journal of Medicine found that combining hepatitis C treatment sofosbuvir with ribavirin for patients who cannot take interferon led to a 78% cure rate after three months of treatment. In patients unresponsive to interferon, the study observed a 73% cure rate after four months of treatment with the two-drug combo. Another study found cure rates of 67% for treatment with either sofosbuvir and ribavirin, or ribavirin and interferon.

View Full Article in:

HealthDay News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA